Symbols

Symbols

AXSM

AXSM

Axsome Therapeutics: Bollinger Bands Narrowing, KDJ Death Cross on 15min Chart

Axsome Therapeutics 15min chart: MACD Death Cross, Bollinger Bands Narrowing detected.

Axsome Therapeutics Securities Litigation Settlement Approved, Class Action.

Friday Nov 07, 2025

Axsome Therapeutics Q3 Results: Analysts Predict 72% Revenue Growth and $0.70 EPS for 2026

Thursday Nov 06, 2025

Axsome Therapeutics' 15min chart shows MACD Death Cross, Bollinger Bands Narrowing

Axsome Therapeutics: Mizuho raises PT to $202 from $200, maintains Outperform.

Avenue Therapeutics' BAER-101 acquired by Axsome Therapeutics for epilepsy treatment.

Axsome acquires AZD7325, a novel oral epilepsy treatment, from AstraZeneca.

Axsome Therapeutics Acquires Baergic Bio from Avenue Therapeutics for up to $82M in Milestones and Royalties

Axsome Therapeutics Acquires AZD7325, a Novel GABA-A Receptor Positive Allosteric Modulator for Epilepsy Treatment

Wednesday Nov 05, 2025

Axsome Therapeutics CEO Tabuteau Herriot Buys, Sells Shares Amid Market Volatility

Axsome Therapeutics' Alzheimer's Disease Agitation sNDA Offers Optionality Without Changing Thesis

Axsome Therapeutics Sees 58% YTD Gain, Analysts Predict Profit Ahead.

Axsome Therapeutics's 15min chart shows bearish indicators and a death cross.

Tuesday Nov 04, 2025

RBC Capital Maintains Axsome Therapeutics (AXSM) Outperform Recommendation with 33.07% Upside Potential

Morgan Stanley Raises Axsome Therapeutics PT to $196, Maintains Overweight Rating

Axsome Therapeutics: HC Wainwright raises PT to $185, maintains Buy rating

Axsome Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales.

Exelon Sees 12% Growth in Data-Center Demand Amid Rising Electricity Consumption

RBC Capital Maintains Outperform Rating on Axsome Therapeutics with PT Raised to $198